Short-term effects of intravitreal ranibizumab therapy on diabetic macular edema

Short-term effects of intravitreal ranibizumab therapy on diabetic macular edema - Short-term effects of intravitreal ranibizumab therapy on diabetic macular edema

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026118

Enrollment

Registered

2017-02-13

Start date

2014-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic macular edema

Interventions

intravitreal ranibizumab injection 0.5 mg/0.05 mL

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The inclusion criteria were the presence of DME before therapy (foveal thickness at baseline was thicker than 300 microns) and no history of ocular surgery (including laser) and/or other treatment for macular edema within the previous 10 weeks.

Exclusion criteria

Exclusion criteria: The exclusion criteria were the logarithm of the minimum angle of resolution (logMAR) VA below 0 (20/200, Snellen equivalent).

Design outcomes

Primary

Measure	Time frame
The Foveal thickness at 2hours, 1day, 1week and 1month after intravitreal ranibizumab injection.	—

Secondary

Measure	Time frame
The visual acuity at 1day, 1week and 1month after intravitreal ranibizumab injection.	—

Countries

Japan

Contacts

Public ContactYoshiro Minami

Nayoro city general hospital medical examination section

y37373m@yahoo.co.jp0165433101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026